CymaBay Therapeutics, a clinical-stage biotech developing treatments for gout and other metabolic and rare diseases, filed on Tuesday with the SEC to raise up to $30 million in an initial public offering. The Newark, CA-based company, which was founded in 1988, plans to list on the NASDAQ under the symbol CBAY. Cowen & Company and Stifel are the joint bookrunners on the deal. No pricing terms were disclosed.
